Valneva SE (LTS:0OB3) Risk Assessment

View and export this data going back to 2011. Start your Free Trial

What is Valneva SE Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Valneva SE is: High Risk: High uncertainty.

Competitive Comparison of Valneva SE's Risk Assessment

For the Biotechnology subindustry, Valneva SE's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valneva SE's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Valneva SE's Risk Assessment falls into.

Valneva SE (LTS:0OB3) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Valneva SE Risk Assessment Related Terms

Thank you for viewing the detailed overview of Valneva SE's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Valneva SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (LTS:0OB3) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

VALN:USA INRLF:USA VLAp:UK VLA:France AYJ:Germany AYJ:Bulgaria VLA:Austria

Address

6 Rue Alain Bombard, Saint-Herblain, FRA, 44800

Website

https://www.valneva.com

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Valneva SE Headlines

No Headlines